In CML, the increased expression of integrin β3 and ILK interaction with β integrins was associated with Imatinib resistance through the activation of PI3K/AKT, STAT3, and ERK1/2 signaling pathways [152]. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.